Information  X 
Enter a valid email address
  Print          More announcements

Thursday 15 July, 2021

JP Morgan Sec LLC

Xeris Pharmaceuticals, Inc 8.3

RNS Number : 4123F
J.P. Morgan Securities LLC
15 July 2021
 

Ap19

 

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

J.P. Morgan Securities LLC

Companydealtin

Xeris Pharmaceuticals, Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

$0.001 common stock

Date of dealing

14 July 2021

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

2,120,213  3.19

166,086  0.25

(2) Derivatives (other than options)

124,887  0.19

4,247  0.01

(3)Optionsandagreementstopurchase/sell

 

 

Total

2,245,100  3.38

170,333  0.26

             

 

 

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit(USD)

 

(Note 5)

Purchase (New Borrow)

 

Purchase (Loan return)

 

Purchases

Purchases

 

Sales

Sales

800

 

7,100

 

5

 3

 

 5

 5

N/A

 

N/A

 

3.6700  USD

3.5200  USD

 

3.6700  USD

3.6000  USD

 

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(USD) (Note 5)

Equity Swap

 

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or   disposal   of   any  relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

  None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

 15 July 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

N/A

If aconnectedEFM,statenatureofconnection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEDZGMNFKRGMZM

a d v e r t i s e m e n t